Company / Gross Profit
AMICUS THERAPEUTICS, INC. Gross Profit History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$561.3M
FY2025
5-year range
$271.0M / $561.3M
FY2021-FY2025
Trend
+18.1%
vs FY2024
Sector context
#14 of 29
Health Care
What the data says
At $561M, AMICUS THERAPEUTICS, INC.'s gross profit ranks #14 of 29 in the Health Care sector. Gross Profit has increased for 9 consecutive years, from $4M in FY2016 to $561M in FY2025.
Based on SEC 10-K filings.
$561M in FY2025 with a 5-year CAGR of +19.6%.
Improved from $362M to $561M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +24.5%
- 5-Year CAGR
- +19.6%
- 10-Year CAGR
- -
Sector benchmark
#14 of 29 in Health CareTop 48% of 29This company $561.3M Sector average $3.5B
▼
-83.8% below sector average
Key checks
Key Insights
- AMICUS THERAPEUTICS, INC.'s gross profit has grown for 9 consecutive years.
- 5-year CAGR of +19.6%, indicating consistent growth.
- In FY2025, gross profit increased 18.1% year-over-year.
- Ranks #14 out of 29 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $561.3M | +18.1% |
| FY2024 | $475.4M | +31.3% |
| FY2023 | $362.0M | +24.6% |
| FY2022 | $290.6M | +7.2% |
| FY2021 | $271.0M | +17.9% |
| FY2020 | $229.8M | +43.4% |
| FY2019 | $160.3M | +108.6% |
| FY2018 | $76.8M | +150.3% |
| FY2017 | $30.7M | +644.1% |
| FY2016 | $4.1M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026